[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-cancer-stage-iv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-cancer-stage-iv":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100610115","phase-2-high-cardiovascular-risk-intervention-with-cardio-oncology-consultation-for-prostate-cancer-following-androgen-receptor-pathway-inhibitor-arpi-therapy-heart-safe-100610115",false,"NCT07223385","High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)","Inclusion Criteria:\n\n* Prostate cancer with localized, very-high risk, lymph-node positive, and\u002For metastatic (Stage IV) disease.\n* Being treated with ARPI therapy with intended duration ≥ 18 months.\n* Age \\> 65 years old and at least one CV risk factor, or age 45-65 years with at least two CV risk factors:\n\n  * Hypertension\n  * Hyperlipidemia\n  * Diabetes mellitus\n  * Family history of early CAD (male first-degree relative (father or brother) with CAD before age 55; female first-degree relative (mother or sister) with CAD before age 65)\n  * Presence of coronary artery calcium (CAC) on chest CT imaging\n* ECOG 0-2\n* Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n\nExclusion Criteria:\n\n* Prior ARPI therapy exposure \\> 6 months duration.\n* Established care with cardio-oncologist (cardiologist with expertise in CV risks of cancer and cardiotoxic cancer therapies).","MALE","45 Years",{"count":18,"type":19},80,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","In patients with prostate cancer (PC), cardiovascular disease (CVD) causes significant morbidity and is the second leading cause of death. Both pre-existing CVD and the use of androgen deprivation therapy (ADT)-a key cornerstone of treatment for men with locally advanced or metastatic PC1,2 contribute to increased CV risk. ADT has been associated with adverse metabolic effects, including increased central adiposity, elevated low-density lipoprotein (LDL) levels, impaired glycemic control, and arterial wall remodeling and endothelial dysfunction\n\nThe data demonstrates that for most patients, the status quo is insufficient6 and there remains a critical gap in the early identification of high CV-risk PC patients who may benefit most from aggressive risk mitigation strategies. Mitigation strategies, like the addition of statins as primary prevention, have shown decrease in MI\u002FCHD death across thousands of patients. Age-related expansion of hematopoietic clones carrying recurrent somatic mutations, termed clonal hematopoiesis of indeterminate potential (CHIP) has recently been identified as a significant driver of atherosclerosis, doubling the risk of coronary heart disease. Notably, while CHIP is detectable in \\~10% of persons over 70 years old, it is enriched in patients with solid malignancies, and radiotherapy exposure is among the most decisive risk factors for developing CHIP12-15. The inflammation-related metabolic signals are activated androgen signaling and exacerbated in patients with CHIP. However, the mechanistic link and clinical consequence are less understood. Therefore, it is critical to study the CV impact of CHIP and metabolic perturbations in patients with PC treated with ARSI therapy.\n\nWe plan to address these critical gaps by testing our innovative hypothesis that early cardio-oncology intervention with aggressive guidelines-based CV optimization during ARPI therapy will reduce CV risk and that CHIP and metabolomics will help identify adverse metabolic remodeling to improve CV risk prediction.\n\nRobust epidemiological and clinical trial data consistently demonstrate that patients with PC are poorly optimized from a CV risk modification perspective, and existing CV risk models do not perform well in patients with cancer. The data demonstrates that for most patients, the status quo is insufficient and there remains a critical gap in the early identification of high CV-risk PC patients who may benefit most from aggressive risk mitigation strategies.",[25,26,27],"Prostate Cancer (Diagnosis)","Prostate Cancer Stage IV","CV Risk",[29,30,31,32],"High-Risk","Lymph-node positive","ARPI Therapy","CV Risk Factors","RECRUITING","2026-06-24",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":19},"2026-08-01",{"date":41,"type":19},"2030-08",{"name":43,"class":44},"Cedars-Sinai Medical Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":20,"phases":57,"briefSummary":59,"conditions":60,"keywords":72,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":5},"100610263","a-study-of-meaning-centered-therapy-for-mexican-adults-with-advanced-cancer-100610263","NCT07225309","A Study of Meaning-Centered Therapy for Mexican Adults With Advanced Cancer","Trial of Meaning Centered Psychotherapy for Mexican Patients With Advanced Cancer","Patient Eligibility Criteria:\n\nA patient cannot be considered eligible for this study unless ALL of the following conditions are met. Participant eligibility will be determined by an initial EMR review followed by a self-report screener and suicide risk assessment.\n\nInclusion Criteria:\n\nEMR Criteria\n\n\\- Documentation of Disease\n\n* Pathologically confirmed breast, prostate, colorectal, thyroid, cervix, uteri, or lung - solid tumor cancer (either most recent or new diagnosis)\n\n  * Definition of Disease \\[or Measurable Disease\\]\n* Diagnosed with stages III or IV\n\n  * Prior Treatment\n* Receiving ambulatory care at INCan\n\nSelf-Report Criteria\n\n* Age ≥ 18 years\n* Able to read and communicate in Spanish determined by the question: \"Can you read and communicate in Spanish? Yes\u002FNo\"\n* Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention\n* Providing care (or services) to Mexican cancer patients at INCan\n* Has access to internet and an electronic device\n* Agrees to be audio-recorded\n\nExclusion Criteria:\n\nEMR Criteria\n\n* Prior Treatment\n\n  * Received psychological or psychiatric care at INCan in the last 3 months\n  * In the judgment of the treating physician, protocol investigators, and\u002For study staff, presence of cognitive impairment (e.g., delirium or dementia) sufficient to preclude meaningful informed consent and\u002For study participation\n  * Diagnosed with a serious psychiatric condition\n\nSelf-Report Criteria\n\n* Received psychological or psychiatric care outside of INCan in the last 3 months\n* Presence of suicide risk determined by the Columbia-Suicide Severity Rating Scale\n* Too ill to participate determined by the question: \"Do you feel too ill to participate because of communication problems, uncontrollable pain, or other symptoms that prevent you from participating?\"\n\nProvider Eligibility Criteria:\n\nInclusion Criteria Self-Report Criteria\n\n* Age ≥ 18 years\n* Able to read and communicate in Spanish determined by the question: \"Can you read and communicate in Spanish? Yes\u002FNo\"\n* Professional role of administrators, clinicians (e.g., oncologists), mental health providers, supervised therapists-in-training (e.g., graduate students), or other related provider delivering the MCP-L experimental intervention\n* Providing care (or services) to Mexican cancer patients at INCan\n* Has access to internet and an electronic device\n* Agrees to be audio-recorded","ALL","18 Years",{"count":56,"type":19},300,[58],"NA","The purpose of this study is to find out if Meaning-Centered Psychotherapy for Latinos (MCP-L) helps reduce anxiety and depression and improves quality of life compared to cognitive behavioral therapy (CBT). Investigators also want to learn what participants and providers think about the therapy, including how the therapy is designed, outside factors, available resources, and how the people involved affect how well MCP-L works.",[61,62,63,64,65,66,67,26,68,69,70,71],"Breast Cancer","Prostate Cancer","Colorectal Cancer","Thyroid Cancer","Breast Cancer Stage III","Breast Cancer Stage IV","Prostate Cancer Stage III","Colorectal Cancer Stage III","Colorectal Cancer Stage IV","Thyroid Cancer Stage III","Thyroid Cancer Stage IV",[73,74,75,76,77,78,79,80,81,82,83,84,85,86],"Breast cancer","Breast cancer Stage III","Breast cancer Stage IV","Prostate cancer","Prostate cancer Stage III","Prostate cancer Stage IV","Colorectal cancer","Colorectal cancer Stage III","Colorectal cancer Stage IV","Thyroid cancer","Thyroid cancer Stage III","Thyroid cancer Stage IV","25-240","Memorial Sloan Kettering Cancer Center","2026-06-18",{"date":89,"type":37},"2026-06-22",{"date":91,"type":37},"2026-05-01",{"date":93,"type":19},"2029-04-13",{"name":86,"class":44}]